Although a number of biomarkers can be used to track features of pulmonary hypertension, no single biomarker is sufficient, according to a new review.
Biomarkers have the potential to help physicians better understand cases of pulmonary hypertension (PH) and other cardiovascular diseases, but a new review article makes clear that the connections are complex, and investigators have not yet reached a point of being able to synthesize multiple biomarker signals into concrete individualized treatment plans.
The new review appears in the Journal of Clinical Medicine. It was authored by Marta Banaszkiewicz, MD, of the European Health Center Otwock in Poland, and colleagues.
The investigators began by noting that the disease—characterized by increased pulmonary vascular resistance—is both progressive and heterogenous, meaning one patient’s case could look very different from the next patient’s case, and a single patient’s disease will evolve and change over time. There are 5 subcategories of the disease, and a patient’s prognosis can vary widely based on the specifics of his or her case.
Such heterogeneity means that the identification of meaningful biomarkers could lead to substantial gains in therapy.
“[B]iomarkers may specifically indicate the disease and provide information about the disease stage and treatment response in a relatively easily accessible and noninvasive way,” Banaszkiewicz and colleagues wrote.
The process of finding novel biomarkers is still a work in progress, the authors said, but the potential exists to find biomarkers that might be able to indicate and differentiate a number of pathophysiological courses of the disease.
The investigators next laid out some of the biomarkers that have already been found. For instance, natriuretic peptides, cardiac troponins, soluble ST2, and heart-type fatty acid-binding protein have been associated with heart failure, myocardial injury, and myocardial remodeling.
At the same time, biomarkers like C-reactive protein and red blood cell distribution width could have implications for the study of PH, the investigators said, given that inflammation is increasingly seen as a potential pathophysiological factor related to the disease.
Banaszkiewicz and colleagues also discussed excessive pulmonary arterial smooth muscle cell proliferation and endothelial dysfunction, noting that pulmonary arterial microcirculation has been associated with 2 types of PH.
They said several biomarkers have been found for both pulmonary arterial smooth muscle cell proliferation and endothelial cells as they relate to PH.
Finally, they said, markers of hypoxia and tissue damage, as well as the concentration of extracellular vesicles may be meaningful biomarkers to investigate, among others.
In their conclusion, the investigators sound a note of caution. While much progress has been made, they wrote that the current knowledge around PH biomarkers represents something akin to puzzle pieces, rather than a complete picture.
“Although a wide range of biomarkers have been explored, none of them are specific enough to be used alone in the diagnostic process and prognosis assessment,” they wrote. “Moreover, the majority of biomarkers mentioned in this review have been evaluated in retrospective studies with a small number of patients and/or controls, divergent studied populations, and with potential selection bias.”
They said bigger trials will be needed to better understand and validate these biomarkers, but also to understand the interplay between them.
“Furthermore, given the complexity of the disease, it remains unlikely that a single biomarker can be used successfully in patients with precapillary PH,” they said.
Reference:
Banaszkiewicz M, Gąsecka A, Darocha S, et al. Circulating blood-based biomarkers in pulmonary hypertension. J Clin Med. Published online January 13, 2022. doi:10.3390/jcm11020383
Initiating BP Medication Linked to Higher Fall, Fracture Risks in Nursing Home Residents
May 2nd 2024Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Read More
Reducing Time Sitting Can Help Lower BP in Older Adults, Randomized Trial Finds
April 20th 2024The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.
Read More
Targeting MACC1 Offers Promising Therapeutic Strategy for PAH
April 10th 2024Positive responses seen following experiments involving metastasis-associated in colon cancer 1 (MACC1) indicate that the biomarker can be used to better diagnose and treat patients with pulmonary arterial hypertension (PAH).
Read More
Pandemic Care Gaps Associated With Loss of Hypertension Control, Study Finds
April 3rd 2024Surprisingly, the investigators found people with uncontrolled hypertension before the pandemic actually had a slightly higher chance of getting their blood pressure under control during the crisis.
Read More